• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Recordati acquires Farma-Projekt in Poland

Recordati acquires Farma-Projekt in Poland

August 3, 2012
CenterWatch Staff

Recordati, a European pharmaceutical group based in Milan, Italy, has agreed to acquire 100% of the share capital of Farma-Projekt, a Polish pharmaceutical company, for $21.5 million.

Farma-Projekt, which earned $14.2 million in sales last year, has operated on the Polish pharmaceutical market since 2003. The company employs 135 personnel and markets cardiovascular and urological treatments, as well as dietary supplements.

“The acquisition of Farma-Projekt is another step forward in our strategy to increase our business in the Central and Eastern European markets which are growing at interesting rates” said Giovanni Recordati, chairman and CEO of Recordati. “Poland has a large population and currently a strong demand for pharmaceuticals. The Polish pharmaceutical market is the second largest in Central and Eastern Europe and in the last five years has been growing at an average annual rate of 6.8%. In particular, the market for self-medication products has grown at an average rate of 11.2% per year.”

Recordati is already present in Poland with its subsidiary Recordati Polska which it established in 2011. The addition of Farma-Projekt will increase it’s presence in Poland.

The transaction is expected to close in the following months.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing